5-lipoxygenase (5-LOX) is a non-heme iron-containing dioxygenase that catalyzes the first committed step in converting arachidonic acid (AA) and Omega-3 polyunsaturated fatty acids (PUFAs) into bioactive lipid mediators. Depending on cellular context, cofactor availability, and substrate, 5-LOX produces either pro-inflammatory leukotrienes or pro-resolving lipoxins and resolvins, making it a molecular switchboard in inflammation and resolution.
Imagine 5-LOX as a factory production line with two separate output belts—one labeled "Attack Mode," the other "Rebuild Mode." Early in an infection or injury, the factory is in Attack Mode: 5-LOX stamps out leukotrienes like ammunition rolling off a wartime assembly line, calling in neutrophils to the battlefield. The foreman (FLAP—5-LOX activating protein) stands at the start of the line, handing 5-LOX the raw material (arachidonic acid) and making sure everything runs fast and hot.
But as the battle winds down—tissue damage is contained, the pathogen is cleared—headquarters sends a new signal. The factory doesn't shut down; it repurposes. The foreman steps aside, and 5-LOX now works with a different crew (15-LOX enzymes from neighboring cells, arriving via "transcellular biosynthesis"). The same production line now stamps out lipoxins and resolvins—cleanup crew signals that tell neutrophils to stand down, macrophages to switch to debris removal, and tissues to start healing. Same enzyme, same substrate family, completely different output. The factory flipped from making grenades to making bandages.
This is why blindly blocking 5-LOX (some asthma drugs tried this) backfires: you stop the attack, but you also stop the rebuild.
5-LOX is a 78 kDa enzyme requiring non-heme iron (Fe²⁺) and calcium (Ca²⁺) for activity. It translocates from cytoplasm to nuclear membrane in response to inflammatory signals:
Leukotriene Synthesis Cascade:
- Activation: Inflammatory stimuli (e.g., LPS, IL-1, TNF) → intracellular Ca²⁺ rise → 5-LOX binds 5-LOX activating protein (FLAP) at nuclear membrane
- Substrate Delivery: Cytosolic phospholipase A2 (cPLA2) liberates arachidonic acid from membrane phospholipids → AA delivered to 5-LOX/FLAP complex
- First Oxygenation: 5-LOX inserts molecular oxygen at carbon-5 position → 5-hydroperoxyeicosatetraenoic acid (5-HPETE)
- LTA₄ Formation: 5-LOX dehydrates 5-HPETE → leukotriene A₄ (LTA₄), an unstable epoxide intermediate
- Branch Point:
- LTB₄ pathway: LTA₄ hydrolase → Leukotriene B4 (LTB₄) → potent neutrophil chemoattractant, binds BLT1 receptor
- Cysteinyl pathway: LTC₄ synthase adds glutathione → LTC₄ → sequential cleavage → LTD₄, LTE₄ (bronchoconstriction, vascular permeability)
When Omega-3 substrates (EPA/DHA) are available and enzymatic microenvironment shifts:
Lipoxin Synthesis (from AA):
- 5-LOX converts AA → 5-HPETE → transferred to 15-LOX (often in adjacent cell type—"transcellular biosynthesis")
- 15-LOX converts 5-HPETE → lipoxin A₄ (LXA₄) or B₄ (LXB₄)
- LXA₄/B₄ bind ALX-FPR2 receptor → stop neutrophil recruitment, promote macrophage efferocytosis, inhibit NF-kB
Resolvin E-series Synthesis (from EPA):
- 5-LOX converts EPA → 5-hydroperoxy-EPA (5-HEPE)
- Further enzymatic steps → Resolvin E-series (RvE1, RvE2, RvE3)
- RvE1 binds ChemR23 and BLT1 (as antagonist) → resolution signaling
Aspirin-Triggered Pathway:
- Aspirin acetylates COX-2 → enzyme activity "flipped" to produce 15R-HETE instead of prostaglandins
- 15R-HETE serves as substrate for 5-LOX → aspirin-triggered lipoxins (ATL) and aspirin-triggered resolvins (AT-RvD1, etc.)
- ATLs are more resistant to metabolic inactivation than native lipoxins
graph TD
AA[Arachidonic Acid] -->|"5-LOX + FLAP"| HPETE[5-HPETE]
HPETE -->|5-LOX| LTA4["LTA₄"]
LTA4 -->|"LTA₄ hydrolase"| LTB4["LTB₄: Neutrophil recruitment"]
LTA4 -->|"LTC₄ synthase"| LTC4["LTC₄ → LTD₄ → LTE₄: Bronchoconstriction"]
HPETE -->|"Transcellular: 15-LOX"| LXA4["LXA₄/LXB₄: Resolution"]
EPA[EPA Omega-3] -->|5-LOX| HEPE[5-HEPE]
HEPE -->|Further steps| RvE["RvE1/E2/E3: Resolution"]
COX2["COX-2 + Aspirin"] -->|Acetylation| 15RHETE[15R-HETE]
15RHETE -->|5-LOX| ATL[Aspirin-Triggered Lipoxins]
LXA4 -->|ALX/FPR2| Resolution["↓ Neutrophils, ↑ Efferocytosis"]
RvE -->|ChemR23, BLT1-antagonism| Resolution
ATL -->|ALX/FPR2| Resolution
The switch from leukotriene to lipoxin/resolvin production involves:
- Substrate availability: EPA/DHA vs AA ratio (Omega-3 index >8% favors resolvins)
- Cofactor presence: Nitric oxide can S-nitrosylate 5-LOX, altering product profile
- Cellular location: Nuclear membrane (FLAP-dependent, leukotrienes) vs cytoplasmic/transcellular (lipoxins/resolvins)
- Temporal signaling: Early inflammation (TNF-α, IL-1β dominance) vs late (lipoxin/resolvin autocrine loops)
- Transcellular biosynthesis: neutrophils generate 5-HPETE → transfer to endothelial cells with 15-LOX → lipoxin completion
5-LOX inhibitors (e.g., zileuton for asthma) block leukotriene synthesis but also impair lipoxins and resolvins production, potentially prolonging unresolved inflammation. This mechanistic insight explains why some anti-leukotriene therapies show paradoxical effects in chronic inflammatory conditions—they halt the attack but prevent resolution.
5-LOX exemplifies Lipid mediator class switching—the temporal reprogramming from pro-inflammatory to pro-resolving lipid mediator synthesis. In healthy resolution, 5-LOX activity persists but product output shifts based on:
- Omega-3 substrate availability (clinical intervention point)
- Transcellular cooperation between cell types
- Aspirin's unique ability to "hijack" COX-2 to feed 5-LOX with resolution substrates
Asthma/Allergic Rhinitis:
- Cysteinyl leukotrienes (LTC₄/D₄/E₄) drive bronchoconstriction
- Elevated urinary LTE₄ (>100 pg/mg creatinine) indicates 5-LOX pathway activation
- Zileuton (5-LOX inhibitor) reduces symptoms but requires monitoring liver enzymes (elevations in ~3% of patients)
Cardiovascular Disease:
- LTB₄ promotes atherosclerosis plaque instability via neutrophil recruitment
- Plasma LTB₄ >50 pg/mL associated with increased MI risk
- Omega-3 supplementation (EPA 2-4g/day) shifts 5-LOX toward resolvin production
Inflammatory Bowel Disease:
- Crohn's disease mucosa shows 5-LOX overexpression and depleted lipoxins
- Omega-3 therapy + aspirin can restore LXA₄ synthesis via 5-LOX pathway
- Fecal LTB₄ >500 pg/g correlates with disease activity
Chronic Pain/Fibromyalgia:
- Persistent 5-LOX-derived leukotriene production without resolution switching
- Low plasma resolvin D1 (<200 pg/mL) and E1 (<50 pg/mL) in fibromyalgia patients
- Intervention: Omega-3 3-4g/day EPA+DHA to provide resolvin substrates
- Metamodel 0 (Evolutionary Mismatch): Modern Omega-3/omega-6 ratios (1:20) vs ancestral (1:1-1:4) chronically bias 5-LOX toward leukotriene production
- Metamodel 1 (Chronic Low-Grade Inflammation): Persistent 5-LOX activation without lipoxin/resolvin switching = metaflammation
- Metamodel 4 (Lipid mediator class switching): 5-LOX is THE exemplar enzyme—temporal control of inflammation-to-resolution transition
- Selfish Immune System: Leukotrienes recruit immune cells (energy-expensive) until resolution signals (lipoxins) restore resource conservation
-
Substrate Modulation:
- Omega-3 supplementation (EPA 2g/day minimum) provides 5-LOX with resolvin precursors
- Reduce arachidonic acid intake (limit red meat, egg yolks if inflammation active)
-
Aspirin Therapy:
- Low-dose aspirin (75-100mg/day) acetylates COX-2 → feeds 5-LOX pathway with ATL substrates
- Contraindicated in aspirin-exacerbated respiratory disease (AERD)—paradoxical leukotriene surge
-
FLAP Inhibition (Emerging):
- Selective FLAP inhibitors preserve non-FLAP-dependent lipoxin synthesis
- Research compounds (not yet clinical) may avoid zileuton's resolution impairment
-
Transcellular Support:
- Anti-inflammatory diet supports 15-LOX function (polyphenols, especially resveratrol)
- Adequate vitamin E (15mg/day) protects 5-LOX from oxidative inactivation
- 5-LOX requires Ca²⁺ (>1 μM intracellular) and non-heme Fe²⁺ for catalytic activity
- FLAP is essential for leukotriene synthesis but NOT for lipoxin production—transcellular pathways bypass FLAP
- LTB₄ is 100-1000× more potent than histamine as neutrophil chemoattractant
- Omega-3 index >8% shifts 5-LOX output from 90% leukotrienes to >50% resolvins (in vitro studies)
- Aspirin-triggered lipoxins (ATLs) resist 15-PGDH degradation, making them 3-5× longer-lived than native LXA₄
- 5-LOX gene polymorphisms (promoter region VNTR) associated with asthma severity and atherosclerosis risk
- Urinary LTE₄ >166 pg/mg creatinine indicates aspirin-exacerbated respiratory disease (AERD)
- Zileuton (5-LOX inhibitor) reduces FEV1 decline in asthma but elevates liver transaminases in 2-4% of patients (monitor ALT monthly for 3 months, then quarterly)
- Resolvins bind G-protein coupled receptors with Kd values in low nanomolar range (RvE1 → ChemR23, Kd ~10 nM)
- 5-LOX knockout mice show impaired bacterial clearance (leukotriene deficiency) AND prolonged inflammation (lipoxin deficiency)—confirming dual role
- lipoxygenase — enzyme superfamily; 5-LOX is the leukotriene/resolvin-producing member
- 12-LOX — produces 12-HETE (pro-inflammatory) and some resolvins; can cooperate with 5-LOX transcellularly
- 15-LOX — critical partner in transcellular lipoxin synthesis; converts 5-LOX product (5-HPETE) → LXA₄
- arachidonic acid — primary substrate for leukotriene synthesis; omega-6 PUFA released by cPLA2
- Omega-3 — EPA/DHA substrates shift 5-LOX toward resolvin production
- leukotrienes — pro-inflammatory products (LTB₄, LTC₄, LTD₄, LTE₄) from AA substrate
- Leukotriene B4 — most potent neutrophil chemoattractant; binds BLT1/BLT2 receptors
- lipoxins — pro-resolving products when 5-LOX works transcellularly with 15-LOX
- resolvins — EPA/DHA-derived resolution mediators (RvE series from 5-LOX + EPA)
- Lipid mediator class switching — 5-LOX exemplifies this temporal transition from inflammation to resolution
- aspirin-triggered resolvins — aspirin acetylates COX-2 → produces 15R-HETE → 5-LOX converts to ATLs and AT-RvDs
- COX-2 — parallel lipid mediator pathway; aspirin-modified COX-2 feeds substrates to 5-LOX for resolution mediators
- neutrophils — recruited by LTB₄; LTB₄ also primes neutrophils for reactive oxygen species production
- efferocytosis — lipoxins and resolvins (5-LOX resolution products) promote macrophage clearance of apoptotic neutrophils
- NF-kB — lipoxins inhibit NF-κB nuclear translocation, stopping pro-inflammatory gene transcription
- ALX-FPR2 receptor — lipoxin and resolvin receptor; activation switches macrophages to M2 phenotype
- inflammation — 5-LOX generates early inflammatory signals (leukotrienes) and late resolution signals (lipoxins/resolvins)
- resolution — 5-LOX product switching is THE mechanism for active resolution; not passive decay
- metaflammation — chronic low-grade inflammation results when 5-LOX stuck in leukotriene mode without resolvin switching
- Chronic Low-Grade Inflammation — persistent 5-LOX leukotriene production without lipoxin/resolvin class switch
- asthma — cysteinyl leukotrienes (5-LOX products) cause bronchoconstriction; zileuton is FDA-approved 5-LOX inhibitor
- atherosclerosis — LTB₄ recruits neutrophils to plaques; lipoxins promote plaque stability
- IBD — 5-LOX overexpressed in Crohn's mucosa; lipoxin deficiency prolongs inflammation
- Omega-3 — substrate availability determines whether 5-LOX makes leukotrienes or resolvins
- transcellular biosynthesis — neutrophil 5-LOX generates 5-HPETE → transferred to endothelial/epithelial 15-LOX → lipoxin synthesis
- Module 1 — Resoleomics, lipid mediator class switching, lipoxins, resolvins, aspirin-triggered lipoxins
- Module 4 — Lipoxygenase pathways, leukotriene synthesis, conversion to LTE₄
- Module 5 — Inflammatory resolution mechanisms, specialized pro-resolving mediators (SPMs)